Review
What is known about community pharmacy supply of naloxone? A scoping review

https://doi.org/10.1016/j.drugpo.2016.02.006Get rights and content

Highlights

  • Take-home naloxone may be expanded through community pharmacy.

  • Early work indicates pharmacists are willing to supply naloxone.

  • Existing models for community pharmacy of naloxone supply exist.

  • Supply models have important cost implications for consumers.

  • Larger implementation studies are needed to determine effectiveness.

Abstract

There is growing evidence that expanded supply of take-home naloxone to prevent opioid overdose deaths is needed. Potential routes for expansion of naloxone provision include through community pharmacies. The aim of this scoping review is to establish what is known about community pharmacy supply of naloxone, in light of unique challenges and opportunities present in pharmacy settings. A scoping review methodology was employed using the six stage iterative process advocated by Arksey and O’Malley (2005) and Levac et al. (2010). Searches used key words and terms such as ‘naloxone’; ‘overdose prevention/drug overdose/opiate overdose’; ‘community/retail pharmacy’; ‘pharmacist/pharmacy/community pharmacy/pharmaceutical services’; ‘professional practice/role’; ‘community care’; attitude of health personnel’; ‘training/supply/cost’. Appropriate search terms were selected for each database. After initial exploratory searches, comprehensive searches were conducted with Cochrane Database of Systematic Reviews, Medline, Medline in Process, Embase, PsycINFO and CINAHL. Eligibility criteria centered on whether studies broadly described supply of naloxone in community pharmacy or had content relating to community pharmacy supply. The search identified 95 articles, of which 16 were related to pharmacy supply of naloxone. Five themes were presented after initial review of the data and consultation with the project Expert Group, and are; ‘Pharmacists Perceptions of Naloxone: Facilitators and Barriers’, ‘Patient Populations: Identification and Recruitment’, ‘Supply Systems and Cost’, ‘Legal Issues’, and ‘Training of Pharmacists and Community Pharmacy Naloxone Recipients’. Findings from this scoping review suggest that community pharmacy based supply of take-home naloxone warrants the community pharmacy based route for distribution of take home naloxone provision warrants further consideration and development. Existing strengths include a range of established supply models, and training curricula, few direct concerns regarding legal liability of pharmacists in the supply of naloxone (once legal supply systems have been established) and the wide range of potential identifiable patient populations, which include pain patients that may not be in contact with existing naloxone supply programmes.

Introduction

With the rising rates of opioid overdose deaths, naloxone has become one of a range of important strategies to address overdose (Straus, Ghitza, & Tai, 2013). Naloxone has been used for more than 40 years to reverse the effects of opioids in clinical and medical settings. Supply of naloxone for bystander administration is more recently becoming a well-established practice in the United States, Canada and the United Kingdom, with numerous studies and reviews confirming the feasibility, efficacy and cost-effectiveness of such programmes (Bennett et al., 2011, Clark et al., 2014, Coffin and Sullivan, 2013, Giglio et al., 2015, Walley et al., 2013).

Community based naloxone for overdose reversal was first implemented through community based initiatives established through peer-led advocacy work, with the Chicago Recovery Alliance prescribing and dispensing naloxone in an outreach model in 1998 (Maxwell, Bigg, Stanczykiewicz, & Carlberg-Racich, 2006). Iinitial models of supply were based in systems that had a strong harm reduction focus and included peer-training through a developed training curriculum, and supply through peer-outreach services (Maxwell et al., 2006). These early programmes, developed through advocacy from organisations oriented towards the needs of people who inject drugs (PWID), described hundreds of reports of successful reversals of opioid overdose in the first published programme descriptions (Maxwell et al., 2006).

In the past 15 years momentum has gathered to expand the reach take-home naloxone programs for opioid reversal within communities and in order to reach the diverse profile of potential recipients. A shift in the nature of opioid dependence and mortality has been observed in some geographic regions over the same time period, from illicit opioids such as heroin to prescription opioids (Maxwell, 2011, Roxburgh and Burns, 2014). The increased role of prescription opioid medication in overdose fatalities, combined with the desire to expand the geographic reach of take-home naloxone initiatives has brought into sharp focus the opportunity for community pharmacy to become an important outlet and harm reduction partner in responding to concerns around opioid-related mortality.

Although benefits of existing models of naloxone supply are clear, with the involvement of peers and programs embedded in services targeted to reach people who use and inject drugs, there may be a number of advantages to expanding the capacity of community pharmacy as a distribution point for take-home naloxone. Community pharmacies already supply medications to the general public and represent widely accessible health care sites in terms of geographic locations and opening hours. Many patients with an overdose risk may not be in contact with existing providers of take-home naloxone. Those not accessing naloxone through existing services may include pain patients using prescription opioids, in addition to those that choose to avoid services identified for people who use drugs due to concerns such as anonymity. In Scotland and England community pharmacy is already well integrated into the harm reduction provider network, with increasing engagement demonstrated over time (Matheson et al., 2007, Sheridan et al., 2007).

Community pharmacy also has some unique challenges when it comes to the supply of naloxone, in contrast with other existing programmes designed to meet the needs of people who use and inject drugs. Attitudes and knowledge in community pharmacy with respect to harm reduction measures vary greatly, with confidence and attitudes being potential barriers to access as seen in other aspects of substance use treatment (Butler and Sheridan, 2010, Hagemeier et al., 2015). In a study from Scotland it was highlighted that some members of the public may not perceive pharmacies as a suitable location for harm reduction services (Gidman & Coomber, 2014). A study conducted in Tijuana, Mexico found that people who use and/or inject drugs may also show reluctance towards accessing harm reduction services in community pharmacies (Davidson et al., 2012). Preliminary work in Indiana, USA, suggests that pharmacists appear interested in further training in the area of substance use and addiction treatment (Wenthur et al., 2013). A further study of pharmacists in Estonia identified that not all pharmacists understand or support the provision of harm reduction (Vorobjov, Uusküla, Abel-Ollo, Talu, & Jarlais, 2009). There is great variation in different countries with the involvement of community pharmacy in different aspects of harm reduction (Hammett et al., 2014). Levels of engagement with harm reduction more broadly vary between the US, Australia, Europe and the United Kingdom (UK), with supervised dosing of opioid substitution treatments for example not being common practice in the US, in contrast with being an accepted practice model in Australia (Green et al., 2015, Watson and Hughes, 2012). Analyses of changing attitudes over time demonstrate that in Scotland, pharmacists have demonstrated a willingness to receive further training, which in turn appears to increase their participation in harm reduction activities (Matheson, Thiruvothiyur, Robertson, & Bond, 2016).

Given the potential to expand the provision of naloxone initiatives for bystander administration through community pharmacy, the aim of this scoping review was to understand what is currently known about community pharmacy supply of naloxone, with a particular focus on understanding current practice and supply models, and barriers that may need to be addressed in order to embed and optimize the expansion of naloxone supply through this community route.

Section snippets

Methods

Scoping review methodologies have become an increasingly popular and adopted approach across a variety of disciplines in recent years (Anderson et al., 2008, Arksey and O’Malley, 2005, Daudt et al., 2013, Levac et al., 2010, Pham et al., 2014). For the purposes of this study, the definition of a scoping review as a type of research synthesis that aims to ‘map the literature on a particular topic or research area and provide an opportunity to identify key concepts; gaps in the research; and

Results

The initial search identified 93 articles, of which 12 were identified to directly relate to community pharmacy supply of naloxone. A further four references were identified through the review process, including conference presentations and articles identified by the project Expert Group. Five themes were explored after initial review of the data and consultation with the scoping review Expert Group. The themes of (1) Pharmacists’ Perceptions of Naloxone: Facilitators and Barriers, (2) Patient

Discussion

The review scoped the extant available literature around what is known about community pharmacy supply of naloxone. We identified a foundation of work which can inform the direction of provision of naloxone to diverse patient groups and their relatives accessing community pharmacy settings. A range of pharmacy specific supply models and logistical barriers were identified. Further work to address these barriers may help harness to capacity of community pharmacy to extend and enhance the reach

Conclusion

Provision of naloxone for bystander administration to prevent opioid overdose deaths appears increasingly feasible and warranted given the rise in rates of overdose deaths. Community pharmacy supply of take home naloxone warrants further development and consideration, in light of general support from the small number of pharmacists included in research so far. Barriers including cost and remuneration for community pharmacists’ time, and how pharmacists may effectively identify and train

Acknowledgements

SN is supported by a NHMRC Research Fellowship (#1013803). The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund. SN is an investigator on a study titled ‘Expanding the capacity of community pharmacy to respond to pharmaceutical opioid problems’, funded by an untied educational grant from Indivior.

Research conducted by MCVH leading to

References (61)

  • S. Anderson et al.

    Asking the right questions: Scoping studies in the commissioning of research on the organisation and delivery of health services

    Health Research Policy and Systems

    (2008)
  • H. Arksey et al.

    Scoping studies: Towards a methodological framework

    International Journal of Social Research Methodology

    (2005)
  • A.M. Bailey et al.

    Naloxone for opioid overdose prevention: Pharmacists’ role in community-based practice settings

    Annals of Pharmacotherapy

    (2014)
  • L. Beletsky et al.

    Prevention of fatal opioid overdose

    JAMA-Journal of the American Medical Association

    (2012)
  • A.S. Bennett et al.

    Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania

    Journal of Urban Health

    (2011)
  • I.A. Binswanger et al.

    Overdose education and naloxone prescribing for patients on chronic opioids: A qualitative study of health care providers

    Journal of General Internal Medicine

    (2014)
  • R. Butler et al.

    Innocent parties or devious drug users: The views of primary healthcare practitioners with respect to those who misuse prescription drugs

    Harm Reduction Journal

    (2010)
  • A.K. Clark et al.

    A systematic review of community opioid overdose prevention and naloxone distribution programs

    Journal of Addiction Medicine

    (2014)
  • P.O. Coffin et al.

    Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal

    Annals of Internal Medicine

    (2013)
  • H.M. Daudt et al.

    Enhancing the scoping study methodology: A large, inter-professional team's experience with Arksey and O’Malley's framework

    BMC Medical Research Methodology

    (2013)
  • C.S. Davis et al.

    Engaging law enforcement in overdose reversal initiatives: Authorization and liability for naloxone administration

    American Journal of Public Health

    (2015)
  • M. Doe-Simkins et al.

    Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study

    BMC Public Health

    (2014)
  • M. Doe-Simkins et al.

    Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose

    American Journal of Public Health

    (2009)
  • K.A. Dong et al.

    Community-based naloxone: A Canadian pilot program

    CJAM Canadian Journal of Addiction Medicine

    (2012)
  • R.R. Fenichel

    Which drugs should be available over the counter? The criteria are clear and include safety, timeliness, and opportunity cost

    BMJ: British Medical Journal

    (2004)
  • H. Firth et al.

    Benefits and barriers to the public health pharmacy: A qualitative exploration of providers’ and commissioners’ perceptions of the Healthy Living Pharmacy framework

    Perspectives in Public Health

    (2015)
  • R.L. Gaston et al.

    Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?

    Harm Reduction Journal

    (2009)
  • S. George et al.

    A guide for clinicians on take home naloxone prescribing

    Addictive Disorders and Their Treatment

    (2008)
  • R.E. Giglio et al.

    Effectiveness of bystander naloxone administration and overdose education programs: A meta-analysis

    Injury Epidemiology

    (2015)
  • T.C. Green et al.

    Case study. Orienting patients to greater opioid safety: Models of community pharmacy-based naloxone

    Harm Reduction Journal

    (2015)
  • Cited by (37)

    • Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a ‘moral hazard’ associated with naloxone supply

      2022, International Journal of Drug Policy
      Citation Excerpt :

      A common objection to THN programs is that they could result in increased risk-taking behaviours in people who use opioids by providing a perceived ‘safety net’ (Green, Bowman et al., 2013; Rudski, 2016). Multiple studies describe how health professionals perceive that the provision of THN may serve to increase opioid use (Bailey & Wermeling, 2014; Nielsen & Van Hout, 2016; Olsen et al., 2019). Similarly, law enforcement officials and policy makers may also hold perceptions of a ‘moral hazard’ and thus object to increasing naloxone coverage (Banta-Green, et al., 2013; Formica et al., 2018; Green, Zaller et al., 2013; Reichert, Lurigio, & Weisner, 2019; Winograd et al., 2020).

    • Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City

      2021, International Journal of Drug Policy
      Citation Excerpt :

      Greater insight into pharmacy-level predictors of buprenorphine availability is needed to inform organizational level interventions to increase buprenorphine availability. Prior literature has disproportionately focused on factors associated with naloxone stocking (Abbas et al., 2021; Carpenter et al., 2019; Egan et al., 2020; Nielson et al., 2016; Nielsen & Van Hout, 2016; Rudolph et al., 2018; Stewart, Thomas, & Tutag-Lehr, 2018; Stone, Hur, & Young, 2020) and naloxone standing order pharmacy programs are shown to increase naloxone stocking (Davis & Carr, 2015; 2017; Gangal et al., 2020; Meyerson et al., 2018; Xu, Davis, Cruz, & Lurie, 2018) yet research is lacking that examines buprenorphine stocking among participating pharmacies. To address gaps in the literature, we examined the relationship between socio-ecological and pharmacy-level factors and the likelihood that pharmacies will report having buprenorphine in stock in a sample of pharmacies in New York City.

    View all citing articles on Scopus
    View full text